Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 20, 2026 2 hours, 2 minutes ago
Medical News: A New Approach to Stroke Treatment Raises Questions
Stroke remains one of the leading causes of death and long-term disability worldwide, and finding better treatments is a constant priority for doctors and researchers. A new study is now shedding light on two emerging injectable therapies—fibrinogenase and direct thrombin inhibitors—that may change how certain stroke patients are treated. While both drugs are designed to prevent dangerous blood clots, their real-world effectiveness has not been fully understood until now.
Targeted stroke therapies may improve recovery by matching treatment to individual blood clot risk
How the Study Was Conducted
Researchers from Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Medical University, Tianjin University, and Tianjin Huanhu Hospital in China analyzed data from 618 patients diagnosed with acute ischemic stroke. These patients were treated between April 2022 and July 2023 and were followed for one year.
The patients were divided into three groups: those receiving fibrinogenase, those treated with direct thrombin inhibitors, and a control group receiving standard care. Scientists carefully tracked stroke recurrence, worsening neurological symptoms during hospitalization, and long-term recovery outcomes.
Key Findings Reveal Unexpected Patterns
The results showed that about 16.3% of all patients experienced a recurrent stroke within one year. Interestingly, recurrence rates were higher in both treatment groups—around 23%—compared to just 9.2% in the control group.
At first glance, this might seem alarming. However, researchers clarified that these drugs were often given to patients already considered at higher risk, which likely explains the difference.
Neurological deterioration during hospital stays was also measured. Patients receiving fibrinogenase had a lower rate of worsening symptoms (4.3%) compared to those receiving direct thrombin inhibitors (12.6%).
The Role of Blood Markers in Treatment Success
A major breakthrough from the study was the discovery of how a blood marker called plasma thromboprotein (TpP) influences treatment outcomes. Patients with higher TpP levels—indicating increased clotting activity—responded particularly well to fibrinogenase therapy.
In this subgroup, fibrinogenase significantly reduced both stroke recurrence and neurological decline. These patients showed consistently better trends compared to others, suggesting that this treatment may work best when targeted to the right individuals.
This
Medical News report highlights that personalized medicine could play a crucial role in future stroke care, especially when guided by measurable biomarkers like TpP.
How These Drugs Work
Fibrinogenase works by breaking down fibrinogen, a key protein involv
ed in clot formation. This helps dissolve existing clots and improves blood flow in the brain. It also enhances the body’s natural clot-dissolving processes.
Direct thrombin inhibitors, on the other hand, block thrombin—a critical enzyme in the clotting process—preventing new clots from forming. However, the study found that while effective in theory, these drugs did not show clear superiority in long-term outcomes.
What This Means for Patients
The findings suggest that fibrinogenase may be a promising option, especially for patients with elevated clotting activity. It appears to offer a better balance between effectiveness and safety, particularly in patients with mild to moderate stroke severity.
However, the study also emphasizes that treatment decisions must be individualized. Not every patient will benefit equally, and factors such as stroke severity, timing, and underlying conditions all play a role.
Study Limitations and Future Directions
As an observational study, the research has limitations. Treatments were not randomly assigned, meaning some bias may exist. Most patients also had relatively mild strokes, so the results may not apply to more severe cases.
Further large-scale clinical trials are needed to confirm these findings and determine how best to use these therapies in everyday medical practice.
Conclusion
This study provides important insights into emerging stroke treatments and highlights the growing importance of personalized care. While both fibrinogenase and direct thrombin inhibitors show potential, fibrinogenase appears particularly beneficial for patients with high clotting activity. With further research, this approach could help doctors better target treatments and improve recovery outcomes for stroke patients worldwide.
The study findings were published in the peer reviewed Journal of Clinical Medicine.
https://www.mdpi.com/2077-0383/15/8/3112
For the latest on treating stroke, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/herbal-compound-cuts-brain-damage-after-stroke
https://www.thailandmedical.news/news/cambridge-study-finds-that-use-of-cannabis-or-other-illicit-drugs-increase-risk-for-stroke
https://www.thailandmedical.news/news/senolytic-drug-navitoclax-protects-brain-after-stroke
https://www.thailandmedical.news/news/thailand-medical-study-identifies-major-risk-factors-behind-ischemic-stroke
https://www.thailandmedical.news/news/thailand-medical-study-finds-common-blood-marker-cannot-reliably-predict-stroke-brain-damage
https://www.thailandmedical.news/news/viral-immune-traps-linked-to-covid-19-stroke-risk
Share
Tweet
Share
